Publication: Principales complicaciones asociadas a la administración de quimioterapia intraperitoneal y endovenosa en pacientes con cáncer de ovario
Authors
Palmés Ferrera, Mercedes ; Andersson Vila, Cassandra Ixena ; Barrera Reyes, María del Carmen ; García Gigán, María del Carmen ; Graells Piqué, María Alba ; Gómez Rodríguez, Esther
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Antecedentes: El cáncer de ovario causa más muertes que cualquier otro tipo de cáncer ginecológico.
La mayoría de casos se diagnostican en una etapa avanzada de la enfermedad y el tratamiento de
elección es generalmente la terapia combinada de quimioterapia intraperitoneal (IP) y endovenosa
(EV). A pesar de que esta opción farmacológica ha demostrado alargar la supervivencia, se han
reportado múltiples efectos adversos asociados a dicho tratamiento.
Objetivo: Identificar los efectos adversos y las complicaciones derivadas del tratamiento con
quimioterapia IP+EV en pacientes con carcinoma de ovario avanzado a partir de estadio IIIC, durante el
periodo 2007-2015.
Metodología: Se realizó un estudio descriptivo, longitudinal y retrospectivo. Un grupo de 17 mujeres
diagnosticadas con cáncer de ovario a partir de estadio III fueron tratadas con quimioterapia IP+EV en
el Hospital Clínic de Barcelona durante el periodo 2007-2015.
Resultados: De las 17 pacientes que recibieron tratamiento con quimioterapia IP+EV, sólo 5 (29,41%)
finalizaron los 6 ciclos de tratamiento. De forma notable, 12 (70,58%) pacientes no completaron el
tratamiento debido a una serie de complicaciones, que fueron frecuentemente asociadas al reservorio
IP y a trastornos psicológicos. Los principales efectos adversos reportados fueron astenia,
neurotoxicidad y dolor abdominal.
Conclusiones: La mayoría de pacientes interrumpieron la terapia debido a complicaciones
relacionadas con el reservorio IP y trastornos psicológicos. Creemos que la enfermera juega un papel
importante, no sólo en el manejo de los aspectos técnicos de la terapia, sino también en el soporte
emocional a dichas pacientes durante esta etapa
ABSTRACT Background: Ovarian cancer displays the highest death rates amongst all gynaecologic cancers. Most cases are diagnosed at an advanced stage of the disease and the treatment of choice is generally the combination therapy of intraperitoneal (IP) and intravenous (IV) chemotherapy. While this approach has been shown to prolong survival, multiple associated toxicities have been reported. Objective: To identify the side effects and complications resulting from IP+IV chemotherapy treatment in stage III and stage IV ovarian cancer patients during the 2007-2015 period. Methods: A descriptive, longitudinal and retrospective study was performed. A group of 17 women diagnosed with stage III and stage IV ovarian cancer were treated with IP+IV chemotherapy in Hospital Clínic de Barcelona during the period 2007-2015. Results: Of the 17 patients who were treated with IP+IV chemotherapy, only 5 (29,41%) completed the 6 cycles of treatment. Notably, 12 (70,58%) patients discontinued the treatment due to a series of complications, which were frequently associated with IP reservoir and psychological disorders. The most commonly reported side effects were asthenia, neurotoxicity and abdominal pain. Conclusions: The majority of patients discontinued their prescribed therapy due to complications associated with IP reservoir and psychological disorders. We believe that the nurse plays a key role, not only in managing the technical aspects of the therapy but also in providing patients with emotional support throughout their journey.
ABSTRACT Background: Ovarian cancer displays the highest death rates amongst all gynaecologic cancers. Most cases are diagnosed at an advanced stage of the disease and the treatment of choice is generally the combination therapy of intraperitoneal (IP) and intravenous (IV) chemotherapy. While this approach has been shown to prolong survival, multiple associated toxicities have been reported. Objective: To identify the side effects and complications resulting from IP+IV chemotherapy treatment in stage III and stage IV ovarian cancer patients during the 2007-2015 period. Methods: A descriptive, longitudinal and retrospective study was performed. A group of 17 women diagnosed with stage III and stage IV ovarian cancer were treated with IP+IV chemotherapy in Hospital Clínic de Barcelona during the period 2007-2015. Results: Of the 17 patients who were treated with IP+IV chemotherapy, only 5 (29,41%) completed the 6 cycles of treatment. Notably, 12 (70,58%) patients discontinued the treatment due to a series of complications, which were frequently associated with IP reservoir and psychological disorders. The most commonly reported side effects were asthenia, neurotoxicity and abdominal pain. Conclusions: The majority of patients discontinued their prescribed therapy due to complications associated with IP reservoir and psychological disorders. We believe that the nurse plays a key role, not only in managing the technical aspects of the therapy but also in providing patients with emotional support throughout their journey.
publication.page.subject
Citation
item.page.embargo
Collections
Ir a Estadísticas
Sin licencia Creative Commons.